TransMedics Group, Inc. - Common Stock (TMDX)
Healthcare › Electromedical & Electrotherapeutic Apparatus
Price History
Feb 9, 2026 — May 16, 2026Investment Snapshot
- Trading 116% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 5/9 — moderate financial health
- ROE of 18.7% — good return on equity
- Revenue growing at 37% annually
TransMedics Group, Inc. - Common Stock (TMDX) is a Healthcare company operating in Electromedical & Electrotherapeutic Apparatus, listed on the NASDAQ , with a market capitalisation of $2.2 billion . Key value metrics: P/E ratio 23.7, P/B ratio 4.42, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
TransMedics Group, Inc. - Common Stock — Fundamental Analysis Summary
TransMedics Group, Inc. - Common Stock (TMDX) is currently trading 116% above its Graham Number of $29.29, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 23.7x.
On financial health, TMDX shows a moderate Piotroski F-Score of 5/9, and solid return on equity of 18.7% (sector average: -20.6%), and manageable leverage with a debt-to-equity ratio of 0.52.
StockPik's composite Value Score for TMDX is 79/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
TMDX reports a solid gross margin of 59.9% (sector average: 40.1%) and a solid operating margin of 16.3%.
TMDX shows revenue growing at 37% year-over-year, with earnings growing at 437%.